Second- and third-line treatment strategies in multiple myeloma: a referral-center experience

The treatment landscape for relapsed multiple myeloma (MM) has increased. In this study, we aimed to characterize 2nd (n = 1439) and 3rd (n = 1104) line regimens and compare the results between subgroups based on the year of treatment initiation (2nd line: 2003–2008, 2009–2015, 2016–2021; 3rd line:...

Descripción completa

Detalles Bibliográficos
Autores principales: Goldman-Mazur, Sarah, Visram, Alissa, Rajkumar, S. Vincent, Kapoor, Prashant, Dispenzieri, Angela, Lacy, Martha Q., Gertz, Morie A., Buadi, Francis K., Hayman, Suzanne R., Dingli, David, Kourelis, Taxiarchis, Gonsalves, Wilson, Warsame, Rahma, Muchtar, Eli, Leung, Nelson, Kyle, Robert A., Kumar, Shaji K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9723783/
https://www.ncbi.nlm.nih.gov/pubmed/36473843
http://dx.doi.org/10.1038/s41408-022-00757-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9723783/
https://www.ncbi.nlm.nih.gov/pubmed/36473843
http://dx.doi.org/10.1038/s41408-022-00757-8

Ejemplares similares